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Aims Pre-eclampsia affects 5–7% of pregnancies, and is a major cause of maternal and foetal death. Elevated serum levels of
placentally derived splice variants of the vascular endothelial growth factor (VEGF) receptor, soluble fms-like tyrosine
kinase-1 (sFLT1), are strongly implicated in the pathogenesis but, as yet, no underlying mechanism has been described.
An excessive inﬂammatory-like response is thought to contribute to the maternal endothelial cell dysfunction that
characterizes pre-eclampsia. We hypothesized that sFLT1 antagonizes autocrine VEGF-A signalling, rendering endo-
thelial cells more sensitive to pro-inﬂammatory factors also released by the placenta. We tested this by manipulating
VEGF receptor signalling and treating endothelial cells with low doses of tumour necrosis factor-a (TNF-a).
Methods
and results
Application of recombinant sFLT1 alone did not activate human umbilical vein endothelial cells (HUVECs). However,
antagonizing the autocrine actions of endothelial VEGF-A and/or placenta growth factor (PlGF) by pre-incubation
with recombinant sFLT1, anti-FLT1, anti-VEGF receptor 2 (KDR), anti-VEGF-A, VEGF receptor tyrosine kinase inhibi-
tor SU5614, or knocking-down FLT1 or KDR transcripts rendered cells more sensitive to low doses of TNF-a.E a c h
treatment increased activation, as measured by increases in endothelial intercellular adhesion molecule 1 (ICAM1),
vascular cell adhesion molecule 1 (VCAM1), endothelin 1 (ET-1), von Willebrand factor (vWF), and leucocyte
adhesion, and led to reduction in AKT Ser
473 and endothelial nitric oxide synthase (eNOS) Ser
1177 phosphorylation.
Conclusions Our data describe a mechanism by which sFLT1 sensitizes endothelial cells to pro-inﬂammatory factors, providing an
explanation for how placental stress may precipitate the pre-eclamptic syndrome.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
Pre-eclampsia is a pregnancy-speciﬁc disorder characterized by
de novo hypertension and proteinuria during the third trimester.
The condition affects 5–7% of pregnancies worldwide and is a
major cause of maternal death, estimated to be in excess of
63 000 a year.
1 Clinical presentation is heterogeneous, but two
forms of the syndrome are now recognized; placental pre-eclampsia
which occurs secondary to defective placentation, and maternal
pre-eclampsia which arises due to a maternal susceptibility to
factors emanating from a normal placenta.
2 The pathophysiology
of placental pre-eclampsia is generally attributed to abnormal con-
version of the maternal spiral arteries supplying the placenta, and
subsequent placental malperfusion. The malperfusion is thought to
result in placental oxidative stress and release of a complex
mix of factors, including pro-inﬂammatory cytokines, apoptotic
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release is believed to culminate in an enhanced maternal inﬂamma-
tory response and systemic endothelial dysfunction leading to the
maternal syndrome.
2–4 To date, however, no single factor has
been identiﬁed that can be considered causal of the syndrome.
2
A signiﬁcant step in unravelling this complexity was made when
Maynard et al.
5 showed that inhibition of vascular endothelial
growth factor (VEGF-A) and placenta growth factor (PlGF) action
through over-expression of soluble fms-like tyrosine kinase-1
(sFLT1) causes a pre-eclampsia-like syndrome in pregnant rats.
Soluble fms-like tyrosine kinase-1 (sFLT1) is formed by alternative
splicing of the pre-mRNA encoding the full-length-signalling
VEGF-R1 (FLT1) receptor, and lacks the cytoplasmic and transmem-
brane domains. sFLT1 antagonizes the pro-angiogenic molecules
VEGF-A and PlGF.
6 In the last 2 months of all pregnancies, maternal
circulating levels of sFLT1 increase, and those of free PlGF decrease.
These changes are more pronounced in women who develop pre-
eclampsia, and occur up to 5 weeks before the onset of clinical symp-
toms.
5,7 Levels of sFLT1 are also raised in pre-eclamptic placentas at
delivery.
5,8 Animal studies provide strong evidence linking sFLT1 to
the pathogenesis of pre-eclampsia. Treatment of pregnant rats with
an adenovirus encoding sFLT1 induces hypertension, proteinuria,
and glomerular endotheliosis, the classical lesion of pre-eclampsia.
5
Additionally, loss of a single VEGF allele in murine glomerular podo-
cytes results in proteinuria and glomerular endotheliosis.
9 Similarly,
administration of a therapeutic VEGF-A neutralizing antibody (Bevaci-
zumab, Avastin Genentech) leads to renal pathology which can be
replicated in adult animals by conditional gene targeting.
10 These
studies all demonstrate that abnormal inhibition of endogenous
VEGF-A activity can induce maternal pre-eclampsia-like symptoms.
Equally, placental malperfusion appears an adequate stimulus for
the release of sFLT1. Uteroplacental ischaemia leads to the elevation
of placental and circulating levels and proteinuria,
11 while the repeti-
tive restriction in blood ﬂow during labour is associated with
increased placental sFLT1 mRNA and protein.
12 sFLT1 secretion is
also induced by hypoxia in primary cytotrophoblast cells,
13 and by
hypoxia,
14 hypoxia-reoxygenation,
15 and tumour necrosis factor-a
(TNF-a)
14 in placental explants.
Despite this strong evidence, the mechanism by which excessive
sFLTI causes maternal endothelium activation is not known. Numerous
papers simply state that sFLT1 is elevated, leading to ‘endothelial dys-
function’.
7,16,17 There is no doubt that endothelial dysfunction does
occur in pre-eclamptic patients,
18 as evidenced by increased markers
of activation, including intercellular adhesion molecule 1 (ICAM1),
19
vascular cell adhesion molecule 1 (VCAM1),
20 endothelin 1 (ET-1),
21
von Willebrand factor (vWF),
22 and thrombomodulin.
23 Whether this
is due to reduced bioavailability of circulating VEGF-A in the maternal
blood due to binding with sFLT1, or to competitive inhibition of full-
length VEGF receptor signalling on the endothelial cell surface is not
known. The ﬁnding that sFLT1 acts synergistically with the soluble
TGF-b co-receptor, endoglin (sENG),
16 to cause endothelial cell acti-
vation suggests the latter may be the case. Additionally, sFLT1 might
play a role in reducing the bioavailability of nitric oxide (NO) by antag-
onizing the effects of VEGF-A, which up-regulates endothelial nitric
oxide synthase (eNOS) mRNA and protein,
24 and sFLT1 might also
reduce VEGF-induced c
1179 phosphorylation.
25
A robust inﬂammatory response is a feature of all pregnancies, and
is further enhanced in pre-eclamptic pregnancies.
26 An excessive
inﬂammatory response has been proposed to be the driving force
that contributes to endothelial cell dysfunction and the clinical syn-
drome of pre-eclampsia.
27 We therefore hypothesized that sFLT1
antagonizes autocrine VEGF-A signalling at the endothelial receptor
level, so rendering endothelial cells more sensitive to
pro-inﬂammatory factors released by the stressed placenta. We
tested this hypothesis by manipulating VEGF receptor signalling by a
wide range of techniques and treating the endothelial cells with low
doses of TNF-a.
2. Methods
2.1 Culture and treatment of HUVECs
Umbilical cords were collected from uncomplicated pregnancies with the
informed written consent of the patients and permission of the Local
Research Ethics Committee (ethical number 03/360). The investigation
also conforms with the principles outlined in the Declaration of Helsinki.
Pools of human umbilical vein endothelial cells (HUVECs) were seeded
into appropriate culture wells and pre-treated the next day for 24 h
with sFLT1 (50–250 ng/mL) and/or neutralizing antibodies, i.e. anti-FLT1
(5 mg/mL), anti-KDR (1 mg/mL), and anti-VEGF-A (5 mg/mL). On Day 3,
sFLT1 was again added to the medium and, where applicable, cells were
pre-incubated with SU5614 (5 mM), LY294002 (0.1–10 mM), or
PF573228 (0.1–10 mM) for 30 min. A low dose of TNF-a (0.5 ng/mL)
was added and cells were incubated for a further 6 h.
2.2 Cell adhesion assay
Pooled HUVECs were seeded into 96-well plates and treated with recom-
binant sFLT1 and TNF-a in quadruplicate, as described above. In the
meantime, differentiated HL60 cells (ECACC European Collection of
Cell Cultures) were spun down and resuspended at 1 × 10
6/mL in phos-
phate buffered saline (PBS). Cells were labelled by incubation at 378C for
20 min in cell tracker green CMFDA (5-chloromethylﬂuorescein diace-
tate) dye (2.5 mM, Invitrogen, Molecular Probes, Paisley, UK). Labelled
cells and an aliquot of retained unlabelled HL60 cells were washed and
resuspended at 5 × 10
5/mL in Dulbecco’s modiﬁed Eagle medium. In
the last hour of the HUVEC TNF-a incubation, 100 mL of HL60 cell sus-
pension was added to each well. The 96-well plate was incubated for the
remaining hour at 378C, followed by aspiration of medium and three
washes with 200 mL PBS. Fluorescence was measured using FLUOstar
Optima Fluorimeter (BMG Labtech, Aylesbury, UK).
2.3 Transfection with siRNAs
Pooled HUVECs were seeded into T25 ﬂasks at 5.0 × 10
5 cells per ﬂask
and incubated overnight. The T25 ﬂasks were incubated with a mixture of
siRNA (100 nM ﬁnal concentration), medium and siFECTamine buffer
(ICVEC, London, UK) for 3 h at 378C, washed and incubated for
further 3 h at 378C. Cells were trypsinized, counted, and seeded into
96-wells or 12-wells at 1 × 10
4 and 5 × 10
4, respectively, and cultured
for 24–48 h. Transfected HUVECs were treated with sFLT1 and the
HL60 adhesion assay and western blots (see Supplementary material
online, Methods) performed. siRNA-mediated knock-down efﬁciency
was checked by quantitative RT–PCR as previously described.
12
2.4 Immunoﬂuorescent cytochemistry and
colorimetric immunohistochemistry
For immunoﬂuorescence, cells were seeded onto gelatin-coated 13-mm
glass cover slips. At the end of the experiment, cells were ﬁxed in 2% par-
aformaldehyde at 48C for 30 min. Cover slips were washed in PBS and, if
not stained immediately, stored in PBS at 48C until required. Cells were
immunostained according to the protocol described previously,
12 which
involved the use of Alexa 488 or Alexa 568 secondary ﬂuorescent anti-
bodies (Invitrogen) and mounting in Vectashield mounting medium
T. Cindrova-Davies et al. 672containing DNA stain DAPI (4′,6-diamidino-2-phenylindole; Vector, UK).
Images were captured and quantiﬁed using a Leica confocal microscope
(LeicaTCS-NT, Leica Instruments GmbH, Germany). All comparable
images, i.e. controls and treated cells, were captured at the same laser
and pinhole setting. At least six ﬁelds per treatment were captured and
quantiﬁed using the Leica software. Values for each treatment were
expressed as cell ﬂuorescence per micrometre. All experiments were
repeated at least three times. We validated the immunoﬂuorescent
quantiﬁcation using FACS analysis (see Supplementary material online,
Methods and Figure S1).
A previously published protocol was followed for immunostaining of
parafﬁn-embedded placental sections,
12 which involved the use of Vectas-
tain Elite ABC kits (Vector Laboratories) and SigmaFast DAB (diamino-
benzidine; Sigma, Poole, UK).
2.5 RNA isolation and quantitative real-time
RT–PCR analysis
Total RNA was isolated from HUVECs using Trizol reagent. The RNA was
quantiﬁed by spectrophotometry (Nanodrop Technologies, Rockland, DE,
USA). In brief, 20 mg of total RNA from each sample was reverse tran-
scribed using a master mix containing SuperScript II Reverse Transcriptase
(Invitrogen). The ABI PRISM 7700 Sequence Detection System (TaqMan)
was used to perform real-time PCR according to the manufacturer’s pro-
tocols. ‘Ct’ values for each transcript were compared with those for 18S
rRNA. All primers and probes were obtained from Applied Biosystems
(ABI, Warrington, UK) ‘Assays-on-Demand’ and used a 5′ FAM reporter
and 3′ non-ﬂuorescent minor groove binder.
2.6 Statistical analysis
All data are presented as means+SEM. Statistical analysis was performed
using Statview (SAS Institute, Inc., Cary, NC, USA). Measurements were
analysed using repeated measures ANOVA. Differences between
two groups were evaluated using Fisher’s Protected Least Signiﬁcant
Difference (PLSD) analysis. In all cases results were considered signiﬁcant
at P , 0.05.
3. Results
3.1 sFLT1 increases activation of HUVECs
in the presence of low doses of TNF-a
Activation of HUVECs was assessed by several means, including
adhesion of ﬂuorescently-labelled HL60 cells, expression of ICAM1,
VCAM1, vWF, and ET-1. sFLT1 treatment alone did not alter HL60
adhesion nor expression of any of the above markers (Figure 1, Sup-
plementary materials online, Figure S2). However, pre-treatment with
increasing doses of sFLT1 followed by stimulation with a low dose of
TNF-a (0.5 ng/mL) led to a signiﬁcant increase in HL60 adhesion
(Figure 1A), and an increase in ICAM1, VCAM1, vWF, and ET-1
(Figure 1B–E, Supplementary material online, Figure S2), compared
with TNF-a treatment alone. On the basis of the dose response,
we chose the concentration of 100 ng/mL of recombinant sFLT1 in
subsequent experiments.
3.2 The effect of sFLT1 can be mimicked at
the RNA and protein level
We speculated that the effects of sFLT1 could be attributed to
reduced availability of autocrine VEGF-A and/or PlGF, or interference
with FLT1/KDR signalling. VEGF acts through two high-afﬁnity recep-
tor tyrosine kinases, FLT1 and KDR, both of which are present in
normal endothelial cells and are up-regulated during angiogenesis.
We thus attempted to mimic the effects of sFLT1 by disrupting
FLT1/KDR signalling at the RNA and protein levels. siRNA was used
to knock down FLT1 and KDR transcripts, while anti- KDR, FLT1,
and VEGF-A neutralizing antibodies and the SU5614 VEGF receptor
tyrosine kinase inhibitor were used to block receptor binding and
activity, respectively. TNF-a treatment of HUVECs transfected with
siFLT1 or siKDR (pools of four oligonucleotides) led to a signiﬁcant
enhancement of cell adhesion, compared with cells transfected with
a control siRNA and treated with TNF-a. In addition, treatment of
the transfected cells with recombinant sFLT1 did not further increase
the TNF-a-induced adhesive capacity of these cells (Figure 2A). Trans-
fection of HUVECs with siTNF-RSF1A served as a control for the cell
adhesion assay, and, as expected, siTNF-RSF1A-transfected cells
showed very little increase in HL60 adhesion upon TNF-a stimulation.
The adhesion of HL60 leucocytes was ICAM1-dependent. ICAM1 is
an endothelial adhesion molecule for neutrophils. siRNA-mediated
ICAM1 knock-down greatly reduced TNF-a-stimulated adhesion,
similar to the response of siTNFR-SF1A-transfected cells (Figure 2A).
Additionally, we tested the speciﬁcity of the siRNA pools using indi-
vidual duplexes for siKDR and siFLT1. Transfection with individual
duplexes increased the sensitivity of HUVECs to the TNF-a treat-
ment and the results were comparable with those obtained with
the siRNA pool (see Supplementary material online, Figure S3). The
efﬁcacy of the knockdown was demonstrated by quantitative RT–
PCR and was .50% (see Supplementary material online, Figure S4).
Simultaneous siRNA-mediated knock-down of both VEGF receptors
resulted in similar enhancement of HL60 adhesion to that observed
when knocking down the individual receptors (see Supplementary
material online, Figure S5).
Similar increases in cell adhesion upon treatment with TNF-a
were observed when HUVECs were pre-treated with neutralizing
antibodies to KDR, FLT1, and VEGF-A, or with the VEGF receptor
kinase inhibitor SU5614 (Figure 2B). Addition of recombinant sFLT1
in conjunction with TNF-a did not further increase HL60
adhesion following any of these pre-treatments. The increase in
adhesion of HL60 cells to HUVECs concomitantly treated with
TNF-a and neutralizing antibodies or SU5614 was associated
with a signiﬁcant increase in ICAM1, VCAM1, vWF, and ET-1
(Figures 2C, 3A–D). Based on these results, which indicate that inhi-
bition/neutralization of either KDR or FLT1 leads to similar
effects as those induced by sFLT1 alone, we inferred that cross-talk
was occurring between these two receptors. Immunoprecipitation
of control or sFLT1-treated cell lysates with anti-KDR and sub-
sequent detection with anti-FLT1 conﬁrmed this. A band corre-
sponding to FLT1 was detected in both cell samples precipitated
with anti-KDR and an additional band corresponding to sFLT1
was present in the sFLT1-treated cell sample (see Supplementary
material online, Figure S6). Thus the two receptors are able to
form a heterodimer.
3.3 Inhibition of the AKT pathway at
protein or RNA level makes HUVECs more
sensitive to TNF-a treatment
We decided to examine the PI3K/AKT pathway as KDR activates the
PI3K/AKT pathway, and VEGF-induced AKT activation stimulates
eNOS Ser
1179 phosphorylation, leading to Ca
2+-independent NO
generation.
25 In addition, VEGF-A up-regulates eNOS mRNA and
protein, thus prolonging the production of the short-lived NO.
24
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concentration-dependent decrease in AKT
Ser473 and eNOS
Ser1177
phosphorylation. Phosphorylation of eNOS at Ser
1177 by AKT leads
to increased NO production.
25,28 Thus the concentration-dependent
decrease in eNOS phosphorylation seen in our study would be
expected to lead to reduced NO production. Total levels of AKT
and eNOS remained unchanged (Figure 4A). This decrease was not
associated with cell death even at high concentrations (data not
shown). Additionally, pre-treatment of HUVECs with recombinant
sFLT1, or anti-FLT1 and anti-KDR antibodies resulted in decreased
phosphorylation of AKT at Ser
473 and decreased phosphorylation of
GSK3 at Ser
21/9 (data not shown). We thus hypothesized that the
increased sensitivity to TNF-a of HUVECs treated with recombinant
sFLT1, neutralizing antibodies or transfected with siKDR or siFLT1
could be due to interference with the AKT-signalling pathway. To
test this, we transfected HUVECs with siAKT1 or siAKT3 (Figure 4B
and C) or pre-treated HUVECs with a PI3-kinase inhibitor, LY294002
(Figure 5), and subsequently tested their sensitivity to TNF-a.W e
chose siAKT1 and siAKT3 based on the placental expression of these
proteins. We found AKT1 in trophoblast and endothelial cells,
whereas AKT3 was only detectable in foetal endothelial cells. In con-
trast, there was no endothelial AKT2, which was only observed in
Figure 1 Pre-treatment of HUVECs with sFLT1 signiﬁcantly increases HL60 leucocyte adhesion, and expression of ICAM1, VCAM1, vWF, and ET-1
upon TNF-a treatment. HUVECs were pre-treated with/without sFLT1 (50–250 ng/mL) for 24 h and subsequently treated with TNF-a for 6 h. Fluor-
escently labelled HL60 leucocytes were added in the ﬁnal hour of TNF-a incubation and ﬂuorescence was detected (A). Fixed HUVECs were immu-
nostained against ICAM1 (B), VCAM1 (C), vWF (D), and ET-1 (E), and ﬂuorescence was quantiﬁed. Experiments were repeated at least three times.
Letters indicate groups signiﬁcantly different using the PLSD test with P , 0.05.
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rendered cells more sensitive to TNF-a, as demonstrated by increased
adhesion of HL60 leucocytes and increased expression of ICAM1
(Figure 4B and C). Knock-down efﬁcacy was determined by western
blotting using anti-AKT1 and AKT3 speciﬁc antibodies (Figure 4B).
Similar effects could be seen in HUVECs pre-treated with different
concentrations of the PI-3 kinase inhibitor, LY294002, which blocks
AKT phosphorylation (Figure 5). The increase in HL60 adhesion in
the LY294002-treated cells was dose-dependant (Figure 5B).
4. Discussion
We have shown that sFLT1 alone does not induce activation of endo-
thelial cells, but that it acts in synergy with TNF-a to enhance the
latter’s pro-inﬂammatory effects. We hypothesized that the synergis-
tic effect is due to antagonism of autocrine VEGF-A signalling. To
conﬁrm this, we mimicked sFLT1 action using neutralizing antibodies
to VEGF-A and its two receptors, a receptor tyrosine kinase inhibitor,
or small inhibitory RNA sequences directed against FLT1 or KDR. All
treatments resulted in greater sensitivity to TNF-a, supporting this
hypothesis.
Autocrine VEGF-A signalling is required for endothelial cell survival in
vivo under non-pathological conditions in a cell-autonomous manner.
EndothelialspeciﬁcablationofVEGF-Aresultsinprogressiveendothelial
degeneration and sudden death of mutant animals.
29 Gerber et al.
30
showed that autocrine VEGF-Aisnecessaryforthe survival ofhaemato-
poietic stem cells. In both these cases, paracrine actions of VEGF-A are
not sufﬁcient to maintain the target cells. Thus, in pre-eclampsia, the
Figure 2 HL60 leucocyte adhesion upon TNF-a treatment is signiﬁcantly increased in HUVECs transfected with siKDR or siFLT1 or treated with
neutralizing antibodies against KDR, FLT1, or VEGF-A or with the VEGF receptor kinase inhibitor SU5614. HUVECs were transfected with siKDR,
siFLT1,s i TNFR-SF1A,o rs i ICAM for 24 h (A), pre-treated with/without sFLT and/or anti-KDR, anti-FLT1 or anti-VEGF-A (B) for 24 h and then
treated with TNF-a for 6 h. Fluorescently labelled HL60 leucocytes were added in the ﬁnal hour of TNF-a incubation and ﬂuorescence was detected.
Western blots were run to detect ICAM1 expression (C). These graphs represent one experimental treatment. Experiments were repeated at least
three times. Letters indicate groups signiﬁcantly different using the PLSD test with P , 0.05. F100—sFLT1 100 ng/mL; T0.5—TNF-a 0.5 ng/mL.
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the circulating VEGF-A and/or PlGF would not be expected to alter the
essential maintenance signals derived from autocrine (endothelial)
VEGF-A. However, if the elevated circulating sFLT1 is able to act in a
dominant-negative fashion at the endothelial cell surface then these
signals would be blocked. Here, we provide several lines of evidence
that support this hypothesis.
FLT1 is known to heterodimerize with KDR
31 and we have shown
that both FLT1 and sFLT1 can be immunopreciptated with anti-KDR
antibodies. Treatment of endothelial cells with agents that block VEGF
receptor signal generation (neutralizing antibodies), reduce receptor
level (siRNA), or inhibit receptor kinase activity (SU5614) all result
in enhanced TNF-a sensitivity, as determined using multiple functional
endpoints.
Furthermore, treatment with sFLT1 or FLT1, KDR or VEGF-A neu-
tralizing antibodies led to reduced phosphorylation of AKT and
reduced phosphorylation of eNOS at Ser
1177. KDR activates the
PI3K/AKT pathway, and VEGF-induced AKT activation mediates
eNOS Ser
1179 phosphorylation, leading to Ca
2+-independent NO
generation.
25 In addition, VEGF-A up-regulates eNOS mRNA and
protein, thus prolonging the production of the short-lived NO.
24
NO and PGI2 (also stimulated by VEGF-A) are mediators of vasodila-
tation, anti-platelet, and anti-thrombotic effects and inhibitors of leu-
cocyte adhesion.
32 Deﬁcient NO production has therefore been
proposed as a mechanism linking the elevation of sFLT1 in pre-
eclampsia. This is further supported by the negative correlation
between plasma or whole blood nitrite concentrations and sFLT1
levels in pre-eclamptic patients, suggesting an inhibitory effect of anti-
angiogenic factors on NO formation.
33 VEGF-receptor activity is an
important regulator of endothelial NO synthesis.
34 Our data suggest
for the ﬁrst time that impaired endothelial function results from
sFLT1 blockade of autocrine VEGF-A action and the subsequent
Figure 3 Treatment of HUVECs with neutralizing antibodies against KDR, FLT1, or VEGF-A or with the VEGF receptor kinase inhibitor SU5614
increases the expression of ICAM1, VCAM1, vWF, and ET-1 upon TNF-a treatment. HUVECs were pre-treated with/without sFLT for 24 h, followed
by a 30-min pre-treatment with/without anti-KDR, anti-FLT1, or anti-VEGF-A and then treated with TNF-a for 6 h. Fixed HUVECs were immunos-
tained against ICAM1 (A), VCAM1 (B), vWF (C), or ET-1(D) and immunoﬂuorescence was quantiﬁed. Each graph represents one experimental treat-
ment. Experiments were repeated at least three times. Letters indicate groups signiﬁcantly different using the PLSD test with P , 0.05. F100—sFLT1
100 ng/mL; T0.5—TNF-a 0.5 ng/mL.
T. Cindrova-Davies et al. 676reduction in AKT-mediated eNOS Ser
1177 phosphorylation. Previous
studies show a strong correlation between phosphorylation of eNOS
and NO production; indeed that AKT-mediated Ser
1177 eNOS phos-
phorylation promotes NO production and that genetic or pharmaco-
logical blockade of this reduces NO production.
25,28
A further vasoprotective function of VEGF-A-induced NO pro-
duction is the ability of NO to inhibit leucocyte rolling and
adhesion in blood vessels which is mediated, at least in part, by
NO action on leucocytes.
35 In our study, phospho-eNOS was
reduced by pre-treatment of HUVECs with sFLT1, which reduced
both AKT Ser
473 and eNOS Ser
1177 phosphorylation. A further
effect of sFLT1 treatment that would increase adhesion was the
induction of surface ICAM1 and VCAM1. This indeed led to
enhanced HL60 adhesion when cells were treated with sub-
maximal doses of TNF-a. Consistent with our in vitro results,
administration of VEGF inhibitors to healthy mice leads to elevated
levels of cytokines that promote metastasis and angiogenesis upon
tumour cell injection.
36 Such activated endothelium could then
facilitate adhesion and egress of tumour cells from the vasculature.
An analogy can be drawn between this situation and that of pre-
eclampsia, where maternal endothelial perturbation leads to vaso-
constriction, manifested as hypertension, increased vascular
Figure 4 The role of the AKT pathway in sFLT1 signalling. Lysates from HUVECs pre-treated with/without sFLT1 (10–200 ng/mL) for 24 h and
subsequently treated with TNF-a for 6 h were immunoblotted with antibodies against P-AKT
Ser473, AKT, P-eNOS
Ser1177, and eNOS (A) and the
signal from three experiments was quantiﬁed (C). HUVECs transfected with siAKT1 or siAKT3 for 24 h and then treated with TNF-a for 6 h were
either immunoblotted with antibodies against AKT1, AKT3, and ICAM1 (B) or incubated with ﬂuorescently labelled HL60 leucocytes in the ﬁnal
hour of TNF-a incubation and ﬂuorescence was detected (D). Each experiment was repeated at least three times. Letters indicate groups signiﬁcantly
different using the PLSD test with P , 0.05. In Figure 4C, lower-case letters compare the signal of P-AKT
Ser473 and capital letters the signal of
P-eNOS
Ser1177. Columns labelled with the same letter do not differ signiﬁcantly. (E) Immunostaining of caesarean delivered placentas for AKT1,
AKT2, and AKT3 localized these to trophoblast and endothelial cells (AKT1), trophoblast only (AKT2), or endothelial cells only (AKT3).
sFLT1 sensitizes endothelial cells to TNF-a 677permeability leading to oedema, and glomerular endotheliosis
causing proteinuria.
2,3
vWF is a well-recognized marker of endothelial dysfunction and cir-
culating levels are elevated in both pre-eclampsia and HELLP syn-
drome (haemolysis, elevated liver enzymes, and low platelet
count).
22 In our experiments, sFLT1 treatment induced little surface
vWF, and low doses of TNF-a only stimulated a moderate increase.
However, sFLT1 and TNF-a acted synergistically to signiﬁcantly
increase vWF surface expression. Thus, sFLT1 antagonizes the vaso-
protective effect of VEGF-A on vascular endothelium.
We selected TNF-a as a representative pro-inﬂammatory cytokine
secreted by the stressed placenta, but other factors, such as IL-1b or
IL-6, may also act in synergy with sFLT1. Animals treated with sFLT1
alone do not develop severe pre-eclampsia and HELLP syndrome, i.e.
no haemolysis or thrombocytopenia.
5 This suggests that other placen-
tally derived soluble factors act in concert with sFLT1 to cause endo-
thelial dysfunction, resulting in severe pre-eclampsia and HELLP. It is
notable that, compared with sFLT1 treatment alone, the combination
of sENG and sFLT1 induced severe clinical signs of pre-eclampsia,
including HELLP syndrome and cerebral oedema, which resembles
eclampsia.
16 Pregnancy is a state of increased inﬂammatory
response
26 and it thus seems that sFLT1 sensitization of maternal
endothelium only leads to endothelial dysfunction in the presence
of other pro-inﬂammatory factors, which are secreted by the placenta
during pregnancy.
Several splice variants of sFLT1 have been identiﬁed; three of which
are known to be up-regulated in placenta of women with pre-
eclampsia and contribute to total sFLT1 production by
cytotrophoblast-like cells in vitro.
37 In this study, we used recombinant
protein encoded by a single splice variant of sFLT1, and it is thus poss-
ible that slightly different results could have been obtained with the
other splice variants. Another potential limitation of this study is
the use of HUVECs to study the effect of sFLT1 and TNF-a.
However, since pre-eclampsia affects a variety of vascular beds, it is
likely that characteristics common to multiple different endothelial
cell types are important. So, while HUVECs are not microvascular
cells, they do share many of the important characteristics exhibited
by such cells isolated from numerous vascular beds.
In conclusion, our study demonstrates that antagonizing the auto-
crine actions of endothelial VEGF-A and/or PlGF by pre-incubation
with recombinant sFLT1, anti-FLT1, anti-KDR, anti-VEGF-A,
SU5614, or knocking-down FLT1 or KDR transcripts, renders the
cells more sensitive to the effects of low doses of TNF-a. Each treat-
ment ultimately led to reduction in AKT Ser
473 and eNOS Ser
1177
phosphorylation (and hence activity) and increased endothelial acti-
vation, as measured by increases in endothelial ICAM1, VCAM1,
ET-1, vWF, and leucocyte adhesion. sFLT1 and TNF-a are both
secreted by the human placenta in response to oxidative stress, and
our data demonstrate a mechanism by which these factors combine
to cause dysfunction of maternal endothelium.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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